Research programme: Alzheimer's disease diagnostics and therapies - Lay Line Genomics
Alternative Names: Anti-Aβ oligomers - LLG; Anti-beta-amyloid oligomers - LLG; Anti-proNerve Growth Factor - LLG; Anti-proNGF - LLG; Diagnostic antibody IM13 - LLG; NGF-based therapy - LLGLatest Information Update: 16 Jul 2016
At a glance
- Originator Lay Line Genomics
- Class Antidementias; Diagnostic agents
- Mechanism of Action Amyloid beta-protein inhibitors; Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Italy
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease(Diagnosis) in Italy
- 20 Jul 2006 Preclinical trials in Alzheimer's disease in Italy (unspecified route)